Drug updated on 4/17/2024
| Dosage Form | Injection (subcutaneous: 60 mg/0.2 mL, 90 mg/0.3 mL, and 120 mg/0.5 mL) |
| Drug Class | Somatostatin analogs |
| Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- Indicated for the long-term treatment of acromegalic patients who have had an inadequate response to or cannot be treated with surgery and/or radiotherapy.
- Indicated for the treatment of adult patients with unresectable, well- or moderately differentiated, locally advanced or metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs) to improve progression-free survival.
- Indicated for the treatment of adults with carcinoid syndrome; when used, it reduces the frequency of short-acting somatostatin analog rescue therapy.
Summary
- Lanreotide (Somatuline Depot) is indicated for the long-term treatment of acromegalic patients who have had an inadequate response to or cannot be treated with surgery and/or radiotherapy. It is also used in treating adult patients with unresectable, well- or moderately differentiated, locally advanced or metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs) to improve progression-free survival and in adults with carcinoid syndrome.
- Six systematic reviews/meta-analyses focused on lanreotide's safety and effectiveness compared to other drugs for similar indications.
- One study highlighted lanreotide’s effectiveness in achieving normal insulin-like growth factor I levels in approximately 70% of patients across three studies. This was achieved through extended dosing intervals which maintained clinical efficacy and safety, as well as health-related quality of life, while providing cost savings compared to standard regimens.
- A study comparing first-generation somatostatin analogs found that lanreotide was preferred over octreotide due to factors related to injection administration. This underlines the importance of considering factors related to administration when evaluating patient experience during treatment decisions.
- In a study focusing on MEN1-related pancreatic NETs (pNENs), both octreotide and lanreotide demonstrated favorable safety profiles with an overall response rate achieved in 88.3% of cases, indicating its effective use even within genetic syndromes associated with NETs.
- Lanreotide has been shown as beneficial when initiated early among asymptomatic individuals suffering from unresectable neuroendocrine tumors, according to a meta-analysis involving diverse treatments including this drug.
Product Monograph / Prescribing Information
| Document Title | Year | Source |
|---|---|---|
| Somatuline depot (lanreotide) Prescribing Information. | 2023 | Ipsen Biopharmaceuticals, Cambridge, MA |
Systematic Reviews / Meta-Analyses
Clinical Practice Guidelines
| Document Title | Year | Source |
|---|---|---|
| Targeting neuroendocrine tumors with octreotide and lanreotide: Key points for clinical practice from NET specialists. | 2023 | Cancer treatment reviews |
| A pituitary society update to acromegaly management guidelines. | 2021 | Pituitary |
| Neuroendocrine and adrenal tumors, version 2.2021, NCCN clinical practice guidelines in oncology. | 2021 | Journal of National Comprehensive Cancer Network |